Daiichi begins Ph IIIb of Lixiana to treat AF

Daiichi Sankyo Co. Ltd. (Tokyo:4568) began the Phase IIIb ENVISAGE-TAVI AF trial to evaluate Lixiana edoxaban (DU-176b) in patients with atrial fibrillation (AF). The open-label, international trial will compare once-daily oral Lixiana vs. a vitamin K antagonist regimen, with or without antiplatelet therapy, in about 1,400 patients following successful transcatheter aortic valve implantation. The primary endpoint is a composite of all-cause death, myocardial infarction (MI), ischemic stroke, systemic embolic events, valve thrombosis and major bleeding...